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Abstract
Objective: To evaluate if gabapentin 600 mg reduces pain after osmotic dilator 
placement the day before a dilation and evacuation (D&E) procedure.
Study Design: We conducted a double-blind, placebo-controlled, randomized 
(stratified by vaginal parity) trial among women undergoing osmotic dilator 
placement before D&E at 15 to 23 5/7 weeks gestation. Subjects received 
gabapentin 600 mg or placebo 30 minutes before dilator placement, with re-dosing 
8 hours later. We assessed pain after dilator placement using a numeric rating scale
(NRS; scale 0-10) at 5 minutes, 2, 4, and 8 hours, and at presentation for D&E. The 
primary outcome was median NRS pain score change from baseline to 8 hours after 
dilator placement. Secondary outcomes included gabapentin-related side effects 
and analgesic use. 
Results: Of 121 randomized women, we excluded three subjects (allergic reaction 
[placebo], randomization error, no NRS data), leaving 60 gabapentin and 58 placebo
subjects. Of 110 (93%) women who provided 8-hour data, median pain score 
changes from baseline did not differ between gabapentin and placebo groups 
overall (2 vs. 2.5, p=0.52), in vaginally nulliparous women (2 vs. 4, p=0.10) or in 
parous women (2 vs. 1.5, p=0.37).  We found no statistically significant differences 
in median pain score change from baseline to any timepoint overall or when 
stratified by parity. Beginning at 2 hours after dilator placement, more gabapentin 
than placebo users experienced dizziness (29/53[55%] vs. 11/53[21%], p=0.001) 
and tiredness (34/54[63%] vs. 17/54[31%], p=0.002). The proportion of women 
using narcotics did not differ between gabapentin (35/60[58%]) or placebo 
(40/58[69%]) users (p=0.26).
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Conclusions: Gabapentin does not reduce pain with overnight osmotic dilator 
placement prior to D&E and causes drug-related side effects. 
Keywords: gabapentin; abortion; dilation and evacuation; osmotic dilators; pain; 
text message
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Implications Statement: Women experience pain, mostly mild to moderate, with 
overnight cervical dilator placement at 15-23 5/7 weeks gestation. About 2/3 of 
women will use a limited quantity of narcotics if provided. Gabapentin does not 
decrease the pain with or following dilator placement and does not decrease 
narcotic use.
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1.0  Introduction
Osmotic dilators are commonly used for cervical preparation prior to dilation 
and evacuation (D&E) procedures. Cervical anesthesia reduces pain with dilator 
placement [1]; however, most research to date has focused on dilators and ease of 
D&E completion, evaluating pain as a secondary outcome [2-5]. Insertion of dilators 
can be more painful than pharmacological cervical preparation, and accounts of 
how this pain changes over time vary [3,4,6]. One trial evaluating use of 
intrauterine lidocaine for pain relief during laminaria placement asked participants 
30 minutes before D&E to self-report their maximum pain level using a visual 
analog scale (VAS) since dilator insertion; mean pain scores for the post-laminaria 
interval were higher than those recorded at laminaria insertion (44 vs 32 p=.04) [2].
Women’s experience with pain during the time between dilator insertion and D&E 
remains an under-evaluated aspect of their abortion experience.
Multimodal pain management is an area of interest across many procedural 
fields. Providers vary in their strategies for pain management after dilator insertion 
and may recommend over-the-counter analgesics alone or prescribe oral narcotics. 
Given the potential for narcotic addiction, studies have been investigating non-
narcotic analgesic adjuncts such as gabapentin for various obstetric and 
gynecologic procedures. Gabapentin is an attractive medication because it is low-
cost, non-addictive, and has few medical contraindications for use [7]. Studies 
regarding preoperative use of gabapentin in abdominal hysterectomy have 
demonstrated decreased post-operative narcotic use, decreased nausea and 
vomiting, and increased patient satisfaction [8-13]. A systematic review 
demonstrated a significant benefit of pre-operative gabapentin for preemptive 
analgesia for abdominal hysterectomy [14]. Data regarding preoperative 
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gabapentin use in other contexts, such as Cesarean delivery and laparoscopic 
ovarian cystectomy, are less consistent [15-20]. The heterogeneity of gabapentin 
dosing and overall pain regimen along with study design limitations make these 
data challenging to generalize to abortion procedures. The goal of this study is to 
evaluate the effect of gabapentin on pain experienced after osmotic dilator 
placement prior to D&E. 
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2.0  Materials and methods
We conducted this randomized, double-blind, placebo-controlled trial at the 
University of California, Davis Medical Center. We enrolled women 15 weeks 0 days 
to 23 weeks 5 days gestation on the day prior to a planned D&E procedure for 
whom the surgical plan included osmotic dilator placement for overnight cervical 
preparation. We included women 18 years or older, English-speaking, with an active
cell phone with text messaging capabilities, and a ride home from clinic. We 
excluded women currently taking gabapentin, with an allergy to gabapentin or our 
standard clinic analgesics (ibuprofen or acetaminophen with codeine), with active 
renal disease, or currently using narcotics. The UC Davis Institutional Review Board 
approved this study and all study subjects gave written consent prior to enrollment. 
After obtaining baseline demographic information, we randomized subjects 
1:1, with stratification based on vaginal parity, to receive two doses of gabapentin 
600 mg or placebo. Subjects took the first study drug dose after randomization and 
instructed to take the second dose 8 hours after dilator placement. The UC Davis 
Investigational Drug Service (IDS) over-encapsulated the study drug and placebo 
tablets to create identical-appearing medication. The IDS performed the 
randomization allocation using a computer-generated random sequence in blocks of
four for two groups (vaginally nulliparous and vaginally parous), prepared 
sequentially numbered vials for each group with appropriate treatment, and 
maintained the randomization log to ensure drug allocation concealment until study
completion.
Family Planning fellows or Obstetrics and Gynecology residents under the 
supervision of Family Planning faculty aimed to place osmotic dilators 30-60 
minutes after intake of the first study drug dose. All physicians followed a 
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standardized clinic protocol for dilator placement (online Appendix Figure 1) using 4
mm Dilapan-S® and cervical anesthesia with lidocaine 1% 20 mL. We used 
adjunctive mifepristone for gestations 22 or more weeks or if the physician placed 
fewer than the preferred number of dilators. Subjects in this study did not receive 
misoprostol. We gave each subject prescriptions for 20 tablets each of ibuprofen 
800 mg (1 tablet every 8 hours as needed) and acetaminophen with codeine 300/30
mg (1-2 tablets orally every 4-6 hours as needed) with instructions to use these 
medications as needed for pain management after dilator insertion.
We evaluated pain using an 11-point numeric rating scale score (NRS; scale 
0-10) and assessed gabapentin-specific side effects of tiredness and dizziness. We 
asked each subject to verbally provide a baseline NRS score and side effect 
responses at the time of study drug intake and then at 5 minutes after dilator 
placement. Each subject received text messages at 2, 4, and 8 hours after dilator 
placement to ascertain current NRS scores for pain, perceived tiredness or 
dizziness, and the quantity of interval analgesic use (ibuprofen and acetaminophen 
with codeine). The 8-hour text included a prompt to take the second dose of study 
drug. Upon presentation for D&E procedure the subsequent day (approximately 18-
24 hours after dilator placement), we asked the subject to verbally provide a NRS 
pain score, current tiredness or dizziness, and analgesic use since the 8-hour text 
message.
The primary outcome was median change in NRS score from baseline to 8 
hours post dilator insertion. We assessed median change in individual pain score 
from baseline, as opposed to median group scores at each time point, because 
using median change in individual pain score has been adopted in other fields as 
the preferred standard for evaluating pain management [20]. Secondary outcomes 
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included pain score change at other time points, difference in pain scores by 
gestational age, study drug side effects, and analgesic use. Additionally, we 
assessed median group pain scores at all post-dilator placement time points to 
describe women’s pain experience with overnight dilator placement. Because 
narcotic pain medications can impact both pain and side effects, we also performed 
an analysis of these outcomes in women who did not use narcotics.
We estimated a sample size based on a prior study that utilized an 11-point 
NRS to assess immediate post dilator pain as a secondary outcome, reporting a 
mean score of 5.2 ± 1.2 [4]. We calculated 12 women per group would demonstrate
a clinically meaningful pain difference of 2-points on NRS with 80% power and 
α=0.05 [21]. We doubled the sample to allow for stratification by vaginal parity, and
then doubled the size again to 48 per group to allow for adequate evaluation of the 
primary and secondary outcomes. We increased the sample by 20% to account for 
incomplete follow-up or other limitations, yielding a final sample of approximately 
120 women.
We performed a modified intention-to-treat analysis, including only women 
who provided any follow-up NRS information. We compared baseline characteristics 
among treatment groups using Fisher’s Exact Test or Chi-square test as indicated, t-
test for continuous variables, and Mann Whitney U for comparing median pain 
scores. We categorized pain scores post hoc as none, mild (1-3), moderate (4-6), or 
severe (7-10). We completed analyses using SPSS version 25 (Armonk, NY).
3.0  Results
We randomized 121 women from March 2017 to April 2018 and excluded 3 
women from the outcome analysis, one due to randomization error, one due to an 
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allergic reaction after dilator placement who had received placebo, and one who did
not provide any follow-up NRS data (Figure 1). The characteristics of the 118 women
(60 in the gabapentin group and 58 in the placebo group) who completed the study 
are presented in Table 1. The mean gestational age for the population was 19 
weeks 3 days. Physicians completed dilator placement 42.3 ± 11.2 minutes after 
initial study drug intake in the gabapentin group and 44.2 ± 9.8 minutes in the 
placebo group (p=0.33). Nine (15%) and 15 (26%) women, respectively, received 
mifepristone. The final study evaluation occurred 22.8 ± 2.0 hours and 22.9 ± 1.8 
hours, respectively, after dilator placement (p=0.91).
Median change in NRS pain score from baseline is presented in Table 2. Fifty-
eight (97%) women in the gabapentin group and 52 (88%) women in the placebo 
group provided 8-hour NRS responses, the primary outcome. Median change in pain
score from baseline to 8 hours post-dilator placement did not differ (2 vs. 2.5, 
p=0.52); this absence of effect persisted at all time points after dilator placement (5
minutes, 2 hours, 4 hours, and 18-24 hours). When evaluating median change in 
NRS scores by parity, we found no statistical differences between gabapentin and 
placebo users at any time point, though we did observe a clinically significant 
difference of 2 points at 5 minutes, 4 hours and 8 hours (Table 2).
When evaluating population median values at each time point, we also found 
no differences in scores at all post-dilator placement time points among treatment 
groups stratified by vaginal parity except for a 2-point difference at 8 hours in 
vaginally nulliparous women (online Appendix Figure 2). Participants provided a 
very wide range of pain scores at each time point.
Women who received gabapentin reported more dizziness or tiredness, both 
of which reached statistical significance compared to placebo beginning at 2-hours 
11
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
after dilator placement (Figure 2). More gabapentin than placebo users experienced
dizziness at 2 (29/53[55%] vs. 11/53[21%], p=0.001), 4 (22/55[40%] vs. 5/50[10%], 
p=0.001) and 8 hours (15/57[26%] vs. 3/52[6%], p=0.004) and tiredness at 2 
(34/54[63%] vs. 17/54[31%], p=0.002) and 4 hours (37/54[69%] vs. 18/51[35%], 
p=0.001). 
Table 3 describes the proportion of women who used pain medication during 
the time from dilator placement to evaluation in the pre-operative area based on 
the 118 women who provided responses to analgesic use questions. Most (98 
[83%]) women used some analgesia, with 85 (73%) women reporting any ibuprofen 
use and 75 (64%) reporting any acetaminophen with codeine use. Women who 
reported higher NRS pain scores more commonly used acetaminophen with codeine
than ibuprofen or no pain medication (Table 3). Acetaminophen with codeine use 
did not differ between gabapentin (35/60[58%]) and placebo (40/58[69%]) users 
(p=0.26). Use of ibuprofen or acetaminophen with codeine did not differ by parity, 
with ibuprofen use by 45 (76%) vaginally nulliparous and 40 (68%) vaginally parous 
women (p=0.4) and acetaminophen with codeine use by 40 (68%) and 35 (59%), 
respectively (p=0.4). Few women (n=12, 10%) reported using six or more 
acetaminophen with codeine tablets, distributed equally among vaginally 
nulliparous (n=6) and parous (n=6) subjects; the maximum number used was 11. 
When stratifying by gestational age (≤19 weeks 6 days or ≥ 20 weeks 0 
days), we found no difference in maximum reported NRS pain score (median 5 vs 6, 
p=0.57) or any acetaminophen with codeine use (46/74 [62%] vs. 29/44 [66%], 
p=0.70). When evaluating pain and side effect outcomes in women who did not use 
any narcotic (25 gabapentin and 18 placebo subjects), we found no difference in 
median 8-hour NRS change from baseline (1 vs. 2, p=0.41), maximum reported NRS
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pain score (median 3 vs 3, p=0.96), or side effect profiles between gabapentin and 
placebo users (data not shown). Sub-analysis of the women who received 
mifepristone showed no difference between gabapentin and placebo users in 
median 8-hour NRS change from baseline (3 vs. 3, p=0.93), maximum reported NRS
pain score (median 7 vs 7, p=0.86) or any acetaminophen with codeine use (5/9 
[56%] vs. 10/15 [67%], p=0.68).
We describe the overall pain experience of women with overnight dilator 
placement by reporting median NRS pain scores and severity for the placebo group 
only in Table 4. Two of these women reported zero on NRS pain scale at all time 
points; both were less than 20 weeks gestation and vaginally parous.
4.0  Discussion
Gabapentin 600 mg with repeat dosing at 8 hours did not improve pain with 
overnight osmotic dilators prior to D&E procedure. Gabapentin had some clinical 
effect as demonstrated by the timely reports of dizziness and tiredness among 
women who received gabapentin compared to placebo, primarily over the first four 
hours after initial ingestion. Since both time points occurred in the afternoon prior to
onset of a typical evening sleeping schedule, we conclude that the excess dizziness 
and tiredness are consistent with known drug side effects. These effects did not 
result in less narcotic use by women receiving gabapentin.
In the subset of vaginally nulliparous women, median pain score changes at 5
minutes, 4 hours, and 8 hours from baseline met our a priori designated 2-point 
clinical difference when comparing gabapentin and placebo groups. Although we 
recruited a study sample large enough for these differences to be assessed, the 
outcomes did not achieve statistical significance. We believe the lack of statistical 
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significance is related to the very wide range in responses in both groups, 
demonstrating the variability in pain experience for each patient. Although 
gabapentin may provide a benefit for vaginally nulliparous women, we found these 
women experienced more dizziness and tiredness without a resultant decrease in 
narcotic use. Thus, the relevant benefit may be negligible. Further research of 
nulliparous women may identify who may benefit from gabapentin prior to osmotic 
dilator placement.
The lack of a clear benefit with gabapentin use correlates with a recently 
reported double-blind randomized trial demonstrating that gabapentin did not 
reduce postoperative pain with first trimester surgical abortion [22]. When 
considering these findings together with the benefit of pre-emptive gabapentin for 
pain reduction with abdominal hysterectomy [8-14], and the slight and variable pain
reduction benefit with cesarean delivery [15-20], perhaps gabapentin is more 
beneficial for incision-related (sensory) pain and less for uterine cramping related 
(visceral) pain.
The medical literature lacks primary data on women’s pain experience with 
dilator placement. Our placebo group provides explicit information about the pain 
experience with overnight dilators. Nulliparous women generally experience 
moderate pain after Dilapan-S placement, commonly peaking at 2 hours, and may 
remain the same for at least 6 more hours. Pain for multiparous women appears to 
peak at 4 hours and decline thereafter. This information will aid providers in patient 
counseling regarding pain expectations in the hours following osmotic dilator 
placement. Future studies should more carefully assess the pain course in vaginally 
nulliparous women more than 8 hours after dilator placement.  
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The broad range of pain scores indicates that some women experience more 
severe pain. By the time of presentation for D&E the next day, the pain level 
reported is lower than what is reported at 8 hours after dilator placement in parous 
women but not in nulliparous women, of whom about 20% are still reporting severe 
pain. We found a correlation of the maximum pain score with acetaminophen with 
codeine use but not with ibuprofen use, demonstrating that women who experience 
severe pain will use a narcotic when available, albeit generally fewer than 6 tablets.
In our practice we now prescribe fewer narcotic tablets initially and have instituted 
a mechanism for providing additional analgesics overnight to women who continue 
to experience pain after finishing their supply.
We measured our dilator placement pain score 5 minutes after dilator 
placement to assess pain free of other factors, including anxiety, that could affect 
pain at the moment of placement.  Prior studies have evaluated pain score at time 
of speculum removal. Schivone et al [23] enrolled 69 women 18 weeks or greater 
(mean 19 weeks) in an open-label randomized trial comparing lidocaine gel and 
lidocaine 1% 12 mL paracervical block for pain control during dilator placement. The
investigators reported a median visual analog scale pain score (based on a 10 cm 
line) of 2.5 cm with gel and 3.9 cm with the paracervical block (p=0.17) with peak 
pain in both groups during dilator placement. Borgatta et al [4] enrolled women 14-
16 weeks gestation who received ibuprofen or ketorolac and a cervical anesthetic 
with lidocaine 1% 10 mL prior to placement of 3-6 osmotic dilators (both laminaria 
and Dilapan, mean 5), resulting in a mean NRS pain score of 5.2 (95% CI 4.0-6.4). 
Our median NRS pain score 5 minutes after dilator placement of 1-2 is much lower 
than reported in both studies, likely reflecting how quickly the pain decreases for 
most women after speculum removal. Of note, the Borgatta et al [4] study did not 
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prescribe oral narcotics to have at home; 2/25 (8%) women made visits to the 
emergency department overnight to obtain narcotic pain medication. The need for 
narcotics in this study may reflect the use of more dilators than needed at this 
gestational age, potentially resulting in more pain [24].
A strength of our study is its large size which allowed ample numbers to 
evaluate overall outcomes as well as differences related to parity. Additionally, 
physicians minimized variation by maintaining a standardized osmotic dilator 
placement protocol across the five family planning subspecialists, two fellows, and 
residents who provided care to study participants. The study was limited by the 
enrollment criteria stipulating that participants must have a ride home from the 
outpatient osmotic dilator placement visit and must have a private cell phone not 
shared by others; both criteria could disproportionately restrict enrollment of 
women with limited support or resources. Additionally, the findings may be specific 
to the dilator regimen used in these participants and may not apply to other 
osmotic dilator protocols.
Though use of adjunctive non-opioid analgesics remains an important focus 
for abortion care, we showed that gabapentin does not provide benefit for osmotic 
dilator-associated pain compared to placebo. Women experienced gabapentin side 
effects but no primary benefit in pain reduction or decrease in narcotic use. We also
describe that some women experience significant pain with overnight dilator 
placement and may utilize a narcotic prescription. The decision to prescribe 
narcotics should be individualized based on discussions with the patient. The 
description of the pain women experience following dilator insertion and the 
associated analgesic use will allow clinicians to provide better counseling and 
adequately titrate pain medication prescriptions.
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Figure 1. Flow and follow-up completion of subjects receiving gabapentin 
or placebo with cervical dilator placement before dilation and 
evacuation procedure
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Figure  2.  Gabapentin-related  side  effects  of  dizziness  and  tiredness  in
subjects  receiving  gabapentin  or  placebo  with  osmotic  dilator  placement
before dilation and evacuation procedure (N=118)
Figure 2A. Dizziness after osmotic dilator placement
Figure 2B. Tiredness after osmotic dilator placement
Measured using an 11-point numeric rating scale (scale 0-10).
23
405
406
407
408
409
410
411
412
413
414
415
Table  1.  Baseline  characteristics  of  subjects  randomized  to  receive
gabapentin or placebo with cervical dilator placement before dilation
and evacuation procedure 
Characteristic Gabapentin
n=60
Placebo
n=58
P value
Age (years) 25.4±5.6 27.2±6.1 0.09
Gestational age
15w0d – 19w6d
20w0d – 23w5d
41 (68%)
19 (32%)
33 (57%)
25 (43%)
0.25
Reason for abortion
Unwanted pregnancy
Fetal anomalies
53 (88%)
7 (12%)
51 (88%)
7 (12%)
0.20
Race
White
Black
Asian 
Mixed
Other
Declined
23 (38%)
11 (18%)
7 (12%)
14 (23%)
4 (7%)
1 (2)
34 (59%)
11 (19%)
3 (5%)
5 (9%)
2 (3%)
3 (5%)
0.09
Ethnicity
Hispanic
Non-Hispanic
Declined
43 (72%)
17 (28%)
0
42 (72%)
14 (24%)
2 (3%)
0.32
Education
Has  not  completed  high
school
High school or equivalent
Some college
College or higher
Declined
6 (10%)
30 (50%)
16 (27%)
8 (13%)
0
4 (7%)
15 (26%)
32 (55%)
6 (10%)
1 (2%)
0.017
Gravidity
1
2
3
4
5
6
7 or more
14 (23%)
15 (25%)
11 (18%)
5 (8%)
4 (7%)
4 (7%)
7 (12%)
10 (17%)
13 (22%)
13 (22%)
7 (12%)
3 (5%)
7 (12%)
5 (9%)
0.86
Prior vaginal delivery
0
1
2
3 or more
30 (50%)
16 (27%)
8 (13%)
6 (10%)
29 (50%)
13 (22%)
9 (16%)
7 (12%)
0.93
Prior Cesarean delivery 0.97
24
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417
418
419
0
1
2 or more
45 (75%)
9 (15%)
6 (10%)
44 (76%)
9 (16%)
5 (9%)
Prior miscarriage 12 (20%) 11 (19%) 1.0
Prior abortion 22 (37%) 27 (47%) 0.35
History of anxiety 6 (10%) 9 (16%) 0.42
History of depression 3 (5%) 5 (9%) 0.49
History of chronic pain 0 2 (3%) 0.24
History of drug use
None
Marijuana
Methamphetamine
Multiple drugs
46 (77%)
7 (12%)
4 (7%)
3 (5%)
42 (72%)
11 (19%)
3 (5%)
2 (3%)
0.71
Data presented as mean ± standard deviation or n (%).
w=weeks; d=days
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Table 2. Median change in NRS pain score from baseline among women with osmotic dilators in place prior to
dilation and evacuation procedure
Time after dilator 
placement
Gabapentin
n=60
Placebo
n=59
p-value*
n Median NRS pain
score change
n Median NRS
pain score
change
Total population
(N=118)
5 minutes 60 1 (-6, 10) 58 2 (-5, 8) 0.42
2 hours 54 3.5 (-8, 9) 54 4 (-2, 10) 0.57
4 hours 56 3 (-8, 9) 50 3.5 (-3, 10) 0.39
8 hours 58 2 (-3, 8) 52 2.5 (-5, 10) 0.52
18-24 hours 60 0.5 (-8, 7) 58 1 (-2, 9) 0.23
Vaginally
nulliparous
(n=59)
5 minutes 30 0 (-6, 8) 29 2 (-2, 7) 0.09
2 hours 27 4 (-8, 9) 27 5 (0, 9) 0.26
4 hours 28 3 (-8, 9) 26 5 (-1, 8) 0.35
8 hours 29 2 (-3, 8) 28 4 (-2, 7) 0.10
18-24 hours 30 0.5 (-8, 6) 29 1 (-2, 9) 0.12
Vaginally parous
(n=59)
5 minutes 30 2 (-5, 10) 29 2 (-5, 8) 0.54
2 hours 27 3 (-1, 9) 27 2 (-2, 10) 0.81
4 hours 28 3 (-3, 7) 24 2.5 (-3, 10) 0.93
8 hours 29 2 (-2, 7) 24 1.5 (-5, 10) 0.37
18-24 hours 30 0.5 (-3, 7) 29 1 (0, 8) 0.95
Data presented as median (range)
NRS = Numeric rating scale (overall range 0-10)
*Mann Whitney U test
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Table 3. Maximum NRS pain score with osmotic dilators and use of acetaminophen with codeine and/or ibuprofen
Categorization
of NRS pain
score
Number of
women
reporting NRS
and analgesic
data
n=118
Used
acetaminop
hen with
codeine*
n=75 (64%)
p
value†
Used
Ibuprofen
only
n=23 (20%)
p
value‡
Used no
analgesics
n=20 (17%) p value§
Severe (7-10) 46 (40%) 37 (49%) <0.01 5 (22%) 0.94 4 (20%) 0.02
Moderate (4-6) 34 (29%) 23 (31%) 6 (26%) 5 (25%)
Mild (1-3) 33 (28%) 15 (20%) 10 (43%) 8 (40%)
None (0) 5 (4%) 0 2 (9%) 3 (15%)
Data presented as n (%)
NRS = Numeric rating scale (overall range 0-10)
*Includes women who used both acetaminophen with codeine and ibuprofen
† Chi-square test; p-value is compared to no use of acetaminophen with codeine
‡ Chi-square test; p-value is compared to use of no pain medication
§ Chi-square test; p-value is compared to use of any pain medication
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Table 4. Population median NRS pain scores and proportion with severe pain stratified by vaginal parity among
women receiving placebo with osmotic dilator placement before dilation and evacuation procedure
Time after 
dilator 
placement
Vaginally Nulliparous
(n=29)
Vaginally Parous
(n=29)
p-value*
Number
respondin
g
NRS Median
(range)
Severe pain† Number
respondin
g
NRS Median
(range)
Severe pain†
Baseline 29 0 (0, 6) 0 29 0 (0, 6) 0 0.72
5 minutes 29 2 (0, 9) 3 (10%) 29 2 (0, 8) 3 (10%) 0.88
2 hours 27 6 (0, 10) 9 (33%) 27 3 (0, 10) 7 (26%) 0.09
4 hours 26 5 (0, 8) 7(27%) 24 3.5 (0, 10) 5 (21%) 0.19
8 hours 28 5 (0, 10) 5 (18%) 24 2 (0, 10) 2 (8%) 0.008
18-24 hours 29 2 (0, 10) 6 (21%) 29 2 (0, 8) 2 (7%) 0.51
Data presented as median (range)
NRS = Numeric rating scale (overall range 0-10)
*Mann Whitney U test comparing medians
† Severe pain is NRS score of 7-10
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